KZKsenia N. Zamyatina

Ksenia N. Zamyatina

*This is an algorithmically generated author record based on publicly available information.

Ksenia N. Zamyatina has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Laboratory possibilities of prognosis of local complications in hip replacement

    by Ksenia N. Zamyatina, Larisa B. Gaikovaya, Nadezhda L. Afanasyeva, Alexander N. Tkachenko, Bakhtiyar G. Aliev, Замятина Ксения Николаевна

    BACKGROUND: Endoprosthetics of large joints is a frequently performed operation in traumatology practice. The progression of local infectious sequela among postoperative patients is of major socio-economic importance since more than 30% of cases of inflammatory postoperative reactions are complicated by sepsis. In recent years, new criteria have been sought to assess the risks of infection in the field of surgical intervention, and prognostic scales have also been developed. AIM: The aim of the study was to evaluate the prognostic value of coagulological, biochemical and hematological indicators of the risk of hemorrhagic complications in patients after hip replacement. MATERIALS AND METHODS: The study included 85 patients who were in the clinic of Traumatology and Orthopedics of the I.I. Mechnikov for planned hip replacement. The average age of the patients was 64 ± 10 years. There were 46 women (54%), 39 men (46%). All patients underwent clinical and laboratory examination before surgery, the day after surgery and before discharge. All patients received rivaroxaban (10 mg 1 time/day) after surgery for the prevention of venous thromboembolic complications (46 patients) or apixaban (2.5 mg 2 times/day) (39 patients) during the entire period of stay in the clinic. Retrospectively, depending on the occurrence of complications, the patients were divided into 2 groups: group 1 — 78 patients (42 women and 36 men), whose postoperative period passed without complications, and group 2 — 7 patients (4 women and 3 men), who had hemorrhagic cases. Screening coagulogram (International Normalized Ratio, Activated partial thromboplastin time, fibrinogen) was performed on the STA Compact analyzer (Stago, France), biochemical parameters (alanine aminotransferase, aspartate aminotransferase, creatinine, total calcium, ionized calcium, serum iron, C-reactive protein) were determined on the COBAS Integra 400plus analyzer, hematological parameters on the DxH800 analyzer (Beckman Coulter, USA). RESULTS: A retrospective analysis revealed that a decrease in serum iron in male patients before surgery is a marker of the prognosis of hemorrhagic complications. Prognostic significant laboratory indicators of the development of hemorrhagic complications in patients in the early period after hip replacement include an increase in fibrinogen and C-reactive protein; a decrease in serum iron. During the recovery period, the concentration of C-reactive protein and the relative number of monocytes are the most significant for assessing the risk of complications. CONCLUSIONS: Among the laboratory indicators in the structure of the weight coefficients of the prognosis of complications in patients undergoing hip replacement, it is necessary to evaluate the concentration of serum iron before surgery, especially in men, in the early postoperative period — C-reactive protein, fibrinogen and serum iron and at discharge — C-reactive protein and the number of monocytes as additional criteria for the risk of complications.

  • Open Access

    Laboratory Predictors of Hemorrhagic Complications in Patients With Total Hip Arthroplasty and Treatment With Direct Oral Anticoagulants

    by L. B. Gaikovaya, K. N. Zamyatina, A. N. Tkachenko, I. L. Urazovskaya, D. Sh. Mansurov, A. G. Balgley, V. M. Khaidarov, B. G. Aliyev

    Introduction. Direct oral anticoagulants (DOAC) rivaroxaban and apixaban have significantly reduced the risk of developing venous thromboembolic complications (VTEC). However, the use of DOAC may be associated with a higher risk of bleeding, especially actual in patients after total hip arthroplasty (THA).Material and methods. We enrolled 38 patients with moderate osteoarthritis of the hip joints undergoing THA. The mean age of patients was 58 (33; 85) years. All the patients received rivaroxaban or apixaban in the doses specified by Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Retrospectively, in the postoperative period, the patients were divided into two groups: Group 1 — 31 patients (20 women and 11 men), who had no hemorrhagic complications after hip replacement; and Group 2 — 7 patients (4 women and 3 men) who experienced hemorrhagic events in the form of hematomas in the wound area. Laboratory tests were performed for all patient baseline (1st day of hospitalization), after surgery (1st day after THA), and on the 7th day after THA. Analyses included the determination of hemostasis parameters (INR, aPPT, fibrinogen, D-dimer), hematological (HGB, PLT, RBC) and biochemical parameters (calcium, ionized calcium, serum iron, hs-CRP).Results. The analysis of biochemical parameters in patients with hemorrhagic complications revealed a significant increase of fibrinogen (p=0,023) compared with uncomplicated cases. Serum iron concentration in men with hemorrhagic complications in the postoperative period was significantly lower than in patients without complications. In patients with hemorrhagic complications, the ionized calcium was lower (p=0,032) than in patients without complications, but within the reference values. The hs-CRP concentration in the group with hemorrhagic complications was twice higher than in the group without complication and eight times above the reference values.Conclusion. The concentration of iron in the blood serum in men below 11 mmol/l and a slight hyperfibrinogenemia of 4.65 g/l in all the patients are the risks of developing hematomas in the area of surgery. These parameters should be used to predict the risk of hemorrhagic complications in patients before THA and recommended for control before the surgery and on the 1st day after THA (hs-CRP).


  • Open Access

    Potential for infusion correction of COVID-19-associated endotheliopathy

    by Ionas S. Simutis, Viacheslav A. Ratnikov, Alexey N. Scheglov, Olga V. Nikolaeva, Gennady A. Boyarinov, Alexander A. Sapegin, Larisa B. Gaikovaya, Darya A. Evteeva, Ksenia N. Zamyatina, Бояринов Геннадий Андреевич, et al.

    Aim. To evaluate the relationship between the systemic inflammatory response and the severity of COVID-19-associated endotheliopathy and the effect of succinate-containing crystalloid solution (sodium meglumine succinate) on it in patients with severe COVID-19. Materials and methods. Clinical and laboratory parameters of 53 intensive care unit's patients with COVID-19 complicated by community-acquired bilateral multisegmental pneumonia were analyzed. Intensive therapy complex of 27 patients (study group) included daily infusion of 1.5% solution of sodium meglumine succinate (Reamberin) in the daily dose of 10 ml/kg for at least 11 days (or during the whole stay in the unit). A similar volume of Ringer's solution was present in the control group of 26 patients. The levels of endotheliocytosis, homocysteine, and systemic inflammatory response were determined at all stages of the study. Results. The evaluation of endotheliopathy degree in the meglumine succinate group showed a significant reduction of initially elevated levels of endotheliemia and homocysteinemia at all study stages. The pattern of changes in the study group was highly correlated (r=0.900.96) with the dynamics of systemic inflammatory response parameters-fibrinogenemia, C-reactive protein and interleukin-6 levels. As normalization of the immune imbalance, we regarded the termination of lymphopenia in the Reamberin group. Conclusion. Early inclusion of Reamberin infusion into intensive therapy of severe COVID-19, in comparison with Ringer's solution, leads to significant and stable correction of the severity of systemic inflammatory response, which in turn is naturally reflected in the severity of endothelial dysfunction, multiple organ failure, and also leads to a decrease in 28-day mortality.


  • Dynamics of hemostasis system and c-reactive protein indexes while new oral anticoagulants intake in patients after hip joint endoprosthesis replacement

    by Zamyatina K.N. Zamyatina, Saiganov S.A. Saiganov, Mazurov V.I. Mazurov, Gaykovaya L.B. Gaykovaya, Tkachenko A.N. Tkachenko, Urazovskaya I.L. Urazovskaya, Mansurov D.SH. Mansurov, Khaidarov V.M. Khaidarov, Balgley A.G. Balgley

  • Endothelial injury in severe COVID-19 as a reason for infusion therapy choice

    by A.S. Korotaev, V.A. Ratnikov, I.S. Simutis, G.A. Boyarinov, A.A. Sapegin, L.B. Gaikovaya, G.G. Ivanova, K.N. Zamyatina

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) на выраженность эндотелиальной дисфункции у пациентов с тяжелой формой новой коронавирусной инфекции (COVID-19). МАТЕРИАЛ И МЕТОДЫ В исследование включены 53 пациента с тяжелой формой COVID-19, осложненной двусторонней полисегментарной пневмонией. Все пациенты исходно методом конвертов рандомизированы на две группы. В комплекс терапии пациентов группы исследования (n=27) включена ежедневная инфузия сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) — препарата реамберин в дозе 10 мл на 1 кг массы тела в течение 4 ч однократно с курсом до 11 дней (или на протяжении времени пребывания в отделении реанимации). Пациенты контрольной группы (n=26) получали в качестве инфузионной среды раствор Рингера в том же объеме. В динамике исследовали содержание эндотелиоцитов, гомоцистеина, тромбоцитов и показатели коагулограммы. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Оценка выраженности эндотелиальной дисфункции показала, что у пациентов, получавших реамберин, определялось более выраженное (p<0,05) снижение исходно повышенного уровня эндотелиоцитов и концентрации гомоцистеина на всех этапах исследования. Существенные межгрупповые различия проявлялись начиная со вторых суток наблюдения. Инфузионная коррекция выраженности эндотелиальной дисфункции приводила к снижению частоты тромботических осложнений, вероятности перевода на инвазивную искусственную вентиляцию легких и летальности по сравнению с традиционным подходом. ЗАКЛЮЧЕНИЕ Применение сукцинатсодержащего кристаллоидного раствора (меглюмина натрия сукцината) в комплексной терапии тяжелых форм новой коронавирусной инфекции оправдано более значительной и стойкой коррекцией исходно выраженной дисфункции эндотелия, способствующей снижению количества тромботических осложнений, переводов на инвазивную искусственную вентиляцию легких и летальности.